By Associate Professor Anthony Michael Joshua

Book Chapters

Covelli AM; Joshua AM; Lipa JE; Butler MO; Snell L; Sun A; Wright FC, 2020, 'Merkel Cell Carcinoma', in Surgical Oncology Manual Third Edition, pp. 333 - 343, http://dx.doi.org/10.1007/978-3-030-48363-0_17

Lim DW; Yin L; Racz JM; Joshua AM; Abadir WWK; Butler MO; Lipa JE; Sun A; Wright FC, 2020, 'Non-melanoma Skin Cancer', in Surgical Oncology Manual Third Edition, pp. 383 - 393, http://dx.doi.org/10.1007/978-3-030-48363-0_19

Racz J; Joshua AM; Lipa JE; Sun A; Wright FC, 2016, 'Merkel Cell Carcinoma', in Surgical Oncology Manual, Springer International Publishing, pp. 189 - 196, http://dx.doi.org/10.1007/978-3-319-26276-5_14

Racz J; Joshua AM; Lipa JE; Sun A; Wright FC, 2016, 'Non-melanoma Skin Cancer', in Surgical Oncology Manual, Springer International Publishing, pp. 225 - 232, http://dx.doi.org/10.1007/978-3-319-26276-5_17

Journal articles

Luckett T; Ng CA; Lai-Kwon J; Kee D; Mulhern B; Joshua AM, 2025, 'Uncertainty and hope in people with metastatic uveal melanoma in the era of immunotherapy and targeted treatments: a theory-based qualitative study', BMC Cancer, 25, http://dx.doi.org/10.1186/s12885-025-14368-6

Liu J; Minchom AR; Greystoke A; Evans TRJ; Sarker D; Joshua AM; Morton C; Yau W; Aktas BY; Cosman R; Cohen JE; Edmondson SR; Paull JRA; Jean-Francois BM; Main NJ; Angeles J; Castellarnau A; Cook N, 2025, 'Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors.', J Clin Oncol, pp. JCO2500236, http://dx.doi.org/10.1200/JCO-25-00236

Barnet MB; Jackson KJL; Masle-Farquhar E; Russell A; Burnett DL; Chye A; Jara CJ; Faulks M; Mawson A; Peters TJ; Brink R; Wright K; Allen I; Junankar S; Davis ID; Heller G; Khan Z; Bruce J; Yang C; Prokopec S; Pugh T; Behren A; Hold GL; Zhang F; Cooper WA; Gao B; Nagrial A; Joshua AM; John T; Peters G; Hui R; Boyer M; Blinman PL; Kao SC; Cebon J; Goodnow CC, 2025, 'Common inherited loss-of-function mutations in the innate sensor NOD2 contribute to exceptional immune response to cancer immunotherapy', Proceedings of the National Academy of Sciences of the United States of America, 122, pp. e2314258122, http://dx.doi.org/10.1073/pnas.2314258122

Yu EY; Ferrario C; Linch MD; Stoeckle M; Laguerre B; Arranz JA; Todenhöfer T; Fong PC; Piulats JM; Berry W; Emmenegger U; Mourey L; Joshua AM; Mar N; Appleman LJ; Conter HJ; Gravis G; Li XT; Schloss C; Poehlein C; de Bono JS, 2025, 'Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D', European Urology Oncology, 8, pp. 641 - 651, http://dx.doi.org/10.1016/j.euo.2024.05.013

Williams C; Inderjeeth AJ; Hong W; McKenzie J; Anton A; Weickhardt A; Wong S; Shapiro J; Parente P; Goh J; Torres J; Smith A; Joshua A; Brown S; Steer C; Johns J; Gibbs P; Tran B; Azad AA, 2025, 'Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry study', Clinical Genitourinary Cancer, 23, http://dx.doi.org/10.1016/j.clgc.2025.102345

Kwan EM; Ng SWS; Tolmeijer SH; Emmett L; Sandhu S; Buteau JP; Iravani A; Joshua AM; Francis RJ; Subhash V; Lee S-T; Scott AM; Martin AJ; Stockler MR; Donnellan G; Annala M; Herberts C; Davis ID; Hofman MS; Azad AA; Wyatt AW; TheraP Investigators and the ANZUP Cancer Trials Group , 2025, 'Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial.', Nat Med, http://dx.doi.org/10.1038/s41591-025-03704-9

Lin KL; Talmor B; Crumbaker M; Joshua A, 2025, 'A Review of Hot Flash Management in Patients with Prostate Cancer.', J Clin Endocrinol Metab, http://dx.doi.org/10.1210/clinem/dgaf302

Lucassen MJJ; Bergmann P; Husson O; Banerji U; Basu B; Melero I; Calvo E; Cassier PA; Drilon A; Fong PC; Garralda E; Joshua AM; Lin CC; Lopez J; Moreno V; Minchom A; Plummer R; Postel-Vinay S; Spreafico A; Shimizu T; Yap TA; Yap C; De Bono JS; Steeghs N, 2025, 'Barriers to publishing early phase clinical trials: the oncologists’ perspective', Oncologist, 30, http://dx.doi.org/10.1093/oncolo/oyaf042

Chambers CR; Watakul S; Schofield P; Howell AE; Zhu J; Tran AMH; Kuepper N; Reed DA; Murphy KJ; Channon LM; Pereira BA; Tyma VM; Lee V; Trpceski M; Henry J; Melenec P; Abdulkhalek L; Nobis M; Metcalf XL; Ritchie S; Cadell A; Stoehr J; Magenau A; Chacon-Fajardo D; Chitty JL; O’Connell S; Zaratzian A; Tayao M; Silva AD; Lyons RJ; Goldstein LD; Dale A; Rookyard A; Connolly A; Crossett B; Tran YTH; Kaltzis P; Vennin C; Dinevska M; Croucher DR; Samra J; Mittal A; Weatheritt RJ; Philp A; Monte-Nieto GD; Zhang L; Enriquez RF; Cox TR; Shi YCC; Pinese M; Waddell N; Sim HW; Chtanova T; Wang Y; Joshua AM; Chantrill L; Jeffry Evans TR; Gill AJ; Morton JP; Pajic M; Christ D; Herzog H; Timpson P; Herrmann D, 2025, 'Targeting the NPY/NPY1R signaling axis in mutant p53–dependent pancreatic cancer impairs metastasis', Science Advances, 11, http://dx.doi.org/10.1126/sciadv.adq4416

Conduit C; Inderjeeth AJ; Allen R; Martin AJ; Parulekar W; Mulroe E; McJannett M; Zielinski RR; Thomson A; Tan TH; Sandhu SK; Reaume MN; Pook DW; North SA; Marx GM; Joshua A; Horvath L; McDermott R; Chowdhury S; Chi KN; Zhang AY; Stockler MR; Davis ID; Sweeney CJ, 2025, 'Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)', Future Oncology London England, 21, pp. 627 - 636, http://dx.doi.org/10.1080/14796694.2024.2440277

Jafri Z; Zhang J; O'Meara CH; Joshua AM; Parish CR; Khachigian LM, 2025, 'Interplay between CD28 and PD-1 in T cell immunotherapy', Vascular Pharmacology, 158, http://dx.doi.org/10.1016/j.vph.2024.107461

Emmett L; Subramaniam S; Crumbaker M; Joshua AM; Sandhu S; Nguyen A; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Kumar ASR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; McJannett M; Thomas H; Langford A; Hofman MS; Martin AJ; Davis ID; Stockler MR; Nguyen A; Ravi Kumar AS; Lin P; Butler P; Martin AJ; Zebic D; Mak B; Tankard N; Rana N; Cusick T; Thompson J; Oakes S; Niu C; Thein T; Ford K; Ristevski N; Yip S; Bills M, 2025, 'Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial', Lancet Oncology, 26, pp. 291 - 299, http://dx.doi.org/10.1016/S1470-2045(25)00009-9

Crumbaker M; Shekar S; Lawrence MG; Goldstein LD; Yam AO; Downton T; Begbie S; Zielinski R; Fox W; Araiza N; Yousif J; Ratnayake L; Antonarakis ES; Denmeade SR; Joshua AM, 2025, 'A phase II single arm prospective study of high dose testosterone in combination with carboplatin chemotherapy in late line metastatic castrate-resistant prostate cancer (HIGH-TeCH study).', Journal of Clinical Oncology, 43, pp. 218 - 218, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.218

Crumbaker M; Krieger L; Pook DW; Davis ID; Fontela A; Oldmeadow C; Hurwitz J; Inderjeeth AJ; Dhillon HM; Downton T; Marx GM; Shekar S; Antonarakis ES; Denmeade SR; Anton A; Tan TH; Sharma S; Goh JC; Horvath L; Joshua AM, 2025, 'Bipolar androgen therapy (BAT) for nonmetastatic castration-resistant prostate (nmCRPC) cancer progressing on darolutamide: Working Out M0 BAT (WOMBAT; ANZUP 2201).', Journal of Clinical Oncology, 43, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.tps298

Scheinberg T; Kench JG; Ferguson P; Sutherland S; Stockler MR; Mahon KL; Stricker P; Joshua AM; Woo H; Thanigasalam R; Ahmadi N; Marx GM; Davis ID; Sengupta S; Leslie S; Centenera MM; Butler L; Horvath L, 2025, 'LEEP: A randomised, window of opportunity, neoadjuvant trial examining the pharmacodynamic effects of ribociclib prior to radical prostatectomy for high-risk, localised prostate cancer.', Journal of Clinical Oncology, 43, pp. 392 - 392, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.392

Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt AJ; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Sandhu S; Zhang AY; Hofman MS; Thomas H; Martin AJ; Davis ID; Stockler MR, 2025, 'Overall survival and quality of life with [ ¹⁷⁷ Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901).', Journal of Clinical Oncology, 43, pp. 17 - 17, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.17

Lin KL; Shekar S; Crumbaker M; Joshua AM, 2025, 'Neurokinin-3 Receptor Antagonism for Refractory Hot Flashes in Men', New England Journal of Medicine, 392, pp. 202 - 203, http://dx.doi.org/10.1056/NEJMc2412361

Liu J; Farrow M; Seymour L; Desai J; Loong HH; Ivy P; Koyoma T; Cook N; Blagden S; Garralda E; Massard C; Tolcher AW; Adashek JJ; Zhang L; Zhao S; Shen L; Kurzrock R; El-Deiry WS; Subbiah V; Joshua AM, 2025, 'Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials', Journal of Clinical Oncology, http://dx.doi.org/10.1200/JCO-24-01534

Pham JP; Staeger R; Joshua AM; Liu J; da Silva IP; Dummer R; Goldinger SM, 2025, 'An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanoma', European Journal of Cancer, 214, http://dx.doi.org/10.1016/j.ejca.2024.115121

Lin HM; Scheinberg T; Portman N; Kim RMN; Mellor R; Huynh K; Faulkner AN; Mellett NA; Davis ID; Martin A; Sullivan D; Joshua A; McJannett M; Subhash V; Yip S; Azad AA; Marschner IC; North SA; McDermott RS; Chi KN; Stockler MR; Sweeney CJ; Meikle PJ; Horvath LG, 2025, 'Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)', Annals of Oncology, http://dx.doi.org/10.1016/j.annonc.2025.05.529

Rollin SPG; Lawrence MG; Joshua AM; Selth LA, 2025, 'Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer', Endocrine Related Cancer, 32, http://dx.doi.org/10.1530/ERC-24-0208

Lawrence MG; Keerthikumar S; Townley SL; Clark AK; Cuffe GB; Laven-Law G; Hanson AR; Shrestha RK; Knutson TP; Richards MG; Teng L; Choo N; Crumbaker M; Joshua AM; Corey E; Nelson PS; Dehm SM; Risbridger GP; Tilley WD; Hickey TE; Taylor RA; Selth LA, 2025, 'Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants', European Urology Focus, http://dx.doi.org/10.1016/j.euf.2025.03.017

Dimitriou F; Orloff MM; Koch Hein EC; Cheng PF; Hughes IF; Simeone E; Montazeri K; Grover P; Mehmi I; Gerard CL; Gaudy-Marqueste C; Grob JJ; Michielin O; Hamid O; Long GV; Sullivan R; Kapiteijn E; Johnson DB; Ascierto PA; Joshua AM; Carvajal RD; Butler MO; Hassel JC; Dummer R, 2025, 'Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors', European Journal of Cancer, 214, http://dx.doi.org/10.1016/j.ejca.2024.115161

El-Deiry WS; Bresson C; Wunder F; Carneiro BA; Dizon DS; Warner JL; Graff SL; Azzoli CG; Wong ET; Cheng L; Mani SA; Safran HP; Williams C; Meissner T; Solomon B; Rubin E; Porgador A; Berchem G; Saintigny P; Onn A; Bar J; Berger R; Gantenbein M; Chen Z; de Pádua Souza C; Reis RMV; Sekacheva M; Cervantes A; Dahut WL; Annunziata CM; Gober K; Musallam KM; Al-Shamsi HO; Abu-Gheida I; Salazar R; Limaye S; Aref AT; Reddel RR; Al Homsi MU; Rouf A; Dermime S; Al Suwaidi J; Vlad C; Buiga R; Al Omari A; Abdel-Razeq H; Oñate-Ocaña LF; Nielsen FC; Graham L; Rueter J; Joshua AM; Girda E; Libutti S; Riedlinger G; Salem ME; Farhangfar CJ; Mesa RA; Faltas BM; Elemento O; Pramesh CS; Sengar M; Aoyama S; Ikeda S; Berindan-Neagoe I; Gaddipati H; Kulkarni M; Auzias E; Gerogianni M; Wolikow N; Istolainen S; Schlafrig P; Frankel NZ; Ferraro AR; Palma J; Gimenez AP; Hernando-Calvo A; Felip E; Tsimberidou AM; Herbst RS; Tabernero J; Schilsky RL; Liu J; Lussier Y; Raynaud J; Batist G; Magidi S; Kurzrock R, 2025, 'Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients', Oncotarget, 16, pp. 140 - 162, http://dx.doi.org/10.18632/oncotarget.28703

Sandhu S; Subramaniam S; Thomas H; Tan TH; Goh JC; Dhiantravan N; Weickhardt AJ; Joshua AM; Kirkwood ID; Lee ST; Gedye C; Nguyen A; Pattison DA; Alipour R; Francis RJ; Hofman MS; Martin AJ; Stockler MR; Davis ID; Emmett L, 2025, '¹⁷⁷ Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001).', Journal of Clinical Oncology, 43, pp. 5016 - 5016, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5016

Sacco JJ; Moser JC; Betof Warner A; Sullivan RJ; Davar D; Shoushtari AN; Carvajal RD; Patel SP; Joshua AM; Hassel JC; Navarro M; Marpadga R; Gullo G; Orloff MM, 2025, 'A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor-naïve patients with metastatic uveal melanoma.', Journal of Clinical Oncology, 43, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.tps9597

Horvath L; Lin H-M; Davis ID; Martin AJ; Yeung N; Kim RMN; Portman N; Joshua AM; McJannett MM; Subhash V; Yip S; North SA; McDermott RS; Chi KN; Stockler MR; Sweeney C, 2025, 'Association of circulating immune and metabolic markers with clinical outcomes in the ENZAMET trial (ANZUP 1304).', Journal of Clinical Oncology, 43, pp. 5093 - 5093, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5093

Munzur AD; Herberts C; Kwan EM; Emmett L; Sandhu S; Buteau JP; Iravani A; Joshua AM; Francis RJ; Lee ST; Scott AM; Martin AJ; Stockler MR; Zhang AY; Williams SG; Bacon JVW; Azad A; Davis ID; Hofman MS; Wyatt AW, 2025, 'Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving ¹⁷⁷ Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603).', Journal of Clinical Oncology, 43, pp. 5020 - 5020, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5020

Lemech CR; Cosman R; Humphries TG; Kichenadasse G; Richardson GE; Nagrial A; Teng C; Liu J; Joshua AM; Cohen H; Mo J; Harvey K; Zhang H; Ling Z; King N; Barnett M; Cioffi M; Maurer MA; Getts D; Swarbrick A, 2025, 'First-in-human mRNA CAR therapy: Correlative biomarker analysis from the MT-302 phase 1 study targeting TROP2 in patients with advanced epithelial tumors.', Journal of Clinical Oncology, 43, pp. 2591 - 2591, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.2591

Butler MO; Sacco JJ; Khan S; Orloff MM; Patel SP; Sullivan RJ; Shoushtari AN; Marr BP; Shackleton MJ; Shields CL; Krema H; Lim L-A; Conway M; Young L; Gwadry-Sridhar FH; Joshua AM; Carvajal RD, 2025, 'Global practice patterns and outcomes for metastatic uveal melanoma treated regionally versus systemically.', Journal of Clinical Oncology, 43, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.e23324

Emmett L; Papa N; Subramaniam S; Crumbaker M; Joshua AM; Nguyen A; Weickhardt AJ; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Hofman MS; Sandhu S; Martin AJ; Thomas H; Davis ID; Stockler MR, 2025, 'Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [ ¹⁷⁷ Lu] Lu-PSMA-617 (ANZUP1901).', Journal of Clinical Oncology, 43, pp. 5011 - 5011, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5011

Sabahi Z; Papa N; Fendler WP; Nguyen A; Wong K; Ayati N; Ho B; Chen J; Cusick T; Burger I; Crumbaker M; Marx GM; Sharma S; Frydenberg M; Sandhu S; Davis ID; Stockler MR; Sweeney C; Joshua AM; Emmett L, 2025, 'Prognostic value of PSMA PET against CHAARTED criteria in an ENZAMET sub-cohort.', Journal of Clinical Oncology, 43, pp. 5091 - 5091, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5091

Khoja L; Atenafu EG; Joshua AM, 2025, 'Updated analyses from a global meta-analysis in metastatic uveal melanoma (mUM) to determine progression free and overall survival benchmarks by line of therapy: An international rare cancers initiative (IRCI) ocular melanoma study.', Journal of Clinical Oncology, 43, pp. 9539 - 9539, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.9539

Thavaneswaran S; Lin F; Grady JP; Espinoza D; Huang ML; Chinchen S; Sebastian L; Kansara M; Mersiades T; Lee CK; Desai J; Grimison P; Brown M; Millward M; Harrup R; O’Byrne K; Nagrial A; Craft P; Simes J; Joshua AM; Thomas DM, 2024, 'A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation', Npj Precision Oncology, 8, http://dx.doi.org/10.1038/s41698-024-00698-4

Azad AA; Bressel M; Tan H; Voskoboynik M; Suder A; Weickhardt AJ; Guminski A; Francis RJ; Saghebi J; Dhiantravan N; Joshua AM; Emmett L; Horvath L; Murphy DG; Hsiao E; Balakrishnar B; Lin P; Redfern A; Macdonald W; Ng S; Lee ST; Pattison DA; Nadebaum D; Kirkwood ID; Hofman MS; Akhurst T; Alipour R; Au L; Banks P; Emerson B; Hussain N; Haskali M; Lewin J; Linklater R; Kostos L; Kashyap R; Krishanth P; Kong G; Kumar A; Murphy D; Roselt P; Sandhu S; Scalzo M; Tran B; Wallace R; Spain L; Bourke H; Milton A; Russo D; Bills M; Chew C; Hsieh W; Crouch B; Smyth D; Pandelus S; Lam H; Gan C; Goh J; Scott A; Hafeez U; Ackermann U; Young K; Poon A; Pathmaraj K; Schembri G; Roach P; Bailey D; Hung T; Asad A; Hagan T; Watts J; Campbell E; Chua W; Pal A; Crumbaker M; Nguyen A; Yam A; Chen J; Ardolino L; Kongrak K; Ratnayake L, 2024, 'Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study', Lancet Oncology, 25, pp. 1267 - 1276, http://dx.doi.org/10.1016/S1470-2045(24)00440-6

O'Day RF; Conway RM; Lim LA; Giblin M; Cherepanoff S; Joshua A; McKay D; McKenzie JD; Fog LS; Holly P; Shackleton M; Kee D; Philips C; McKelvie P; Bhikoo R; Hadden P; Negretti GS; Sagoo MS; Damato BE; Sia D; McGrath L; Glasson W; Isaacs T; Gillies M; Barthelmes D, 2024, 'The Fight Tumour Blindness Registry: Efficient capture of high-quality real-world data in uveal melanoma', Canadian Journal of Ophthalmology, 59, pp. e525 - e533, http://dx.doi.org/10.1016/j.jcjo.2024.05.006

Tan Q; Joshua AM; Wang M; Bristow RG; Wouters BG; Allen CJ; Tannock IF, 2024, 'Correction to: Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity (Cancer Chemotherapy and Pharmacology, (2017), 79, 5, (959-969), 10.1007/s00280-017-3298-5)', Cancer Chemotherapy and Pharmacology, 94, pp. 485 - 486, http://dx.doi.org/10.1007/s00280-023-04636-2

Li S; Nguyen A; Counter W; John NC; De Leon J; Hruby G; Joshua AM; Stricker P; Crumbaker M; Ayati N; Chan L; Sabahi Z; Swiha M; Kneebone A; Wong K; Liu V; Sharma S; Agrawal S; Emmett LM, 2024, 'Utility of 64Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68Ga-PSMA-11 PET/CT', Journal of Nuclear Medicine, 65, pp. 1371 - 1375, http://dx.doi.org/10.2967/jnumed.124.267881

Fleshner NE; Bernardino RM; Lajkosz K; Saad F; Izawa J; Drachenberg D; Saranchuk JW; Tanguay S; Rendon RA; Leveridge M; Shayegan B; Fairey A; Cockburn JG; Berlin D; Hamilton RJ; Sildva T; Breau RH; Richard PO; Klotz L; Joshua AM, 2024, 'A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.', Journal of Clinical Oncology, 42, pp. LBA5002 - LBA5002, http://dx.doi.org/10.1200/jco.2024.42.17_suppl.lba5002

Joshua AM; O'day R; Glasson W; Sia D; McGrath L; Ameratunga M; Cosman R; Cherepanoff S; O'Quigley M; Beaupre DM; Conway M; Lim L-A; McKenzie J; McKay D; Shackleton MJ; Fung A; Isaacs T; Yousif J; Brooks C; Psaroulis T, 2024, 'A phase 2 safety and efficacy study of neoadjuvant/adjuvant darovasertib for localized ocular melanoma.', Journal of Clinical Oncology, 42, pp. 9510 - 9510, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.9510

Kwan EM; Hofman MS; Ng SWS; Emmett L; Sandhu S; Buteau JP; Iravani A; Joshua AM; Francis RJ; Subhash V; Lee ST; Scott AM; Martin AJ; Stockler MR; Donnellan G; Annala M; Tolmeijer SH; Azad A; Davis ID; Wyatt AW, 2024, 'Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [¹⁷⁷Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).', Journal of Clinical Oncology, 42, pp. 5055 - 5055, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.5055

Liu JJ; Minchom AR; Greystoke A; Evans TRJ; Sarker D; Joshua AM; Morton C; Aktas BY; Cosman R; Chwialkowska D; Paull J; Main NJ; Jean-Francois BM; Le Meur J; Edmondson SR; Cook N, 2024, 'Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial.', Journal of Clinical Oncology, 42, pp. 3014 - 3014, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.3014

Spicer JF; Pinato DJ; Forster M; Joshua AM; Korolewicz J; Aboud K; Morton C; Liu JJ; Cosman R; Main NJ; Le Meur J; Paull J; Edmondson SR; Jones RH, 2024, 'Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (DEP CTX) in patients with advanced solid cancers in a phase 1/2 trial (P1/2).', Journal of Clinical Oncology, 42, pp. 3004 - 3004, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.3004

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau HT; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; de Spéville BD, 2024, 'First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study', Cancer Research Communications, 4, pp. 1609 - 1619, http://dx.doi.org/10.1158/2767-9764.CRC-23-0459

Ng CA; Luckett T; Mulhern B; Kee D; Lai-Kwon J; Joshua AM, 2024, 'What matters most to people with metastatic uveal melanoma? A qualitative study to inform future measurement of health-related quality of life', Melanoma Research, 34, pp. 248 - 257, http://dx.doi.org/10.1097/CMR.0000000000000961

Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID, 2024, '[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial', Lancet Oncology, 25, pp. 563 - 571, http://dx.doi.org/10.1016/S1470-2045(24)00135-9

Back to profile page